Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: mucomyst Clear all
Completed No phase listed Observational

Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

NCT01465542
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Early Phase 1 Interventional

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

NCT02994875
View directory record Official record
Conditions
Cocaine Dependence
Interventions
N-acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans

NCT00434005
View directory record Official record
Conditions
Healthy
Interventions
N-acetylcysteine, ascorbate, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

NCT02791945
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
Interventions
Medical Management Counseling, N-acetylcysteine, Placebo
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 15, 2026, 5:24 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Insulin Resistance Study

NCT00614757
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome x
Interventions
N-acetylcysteine 20% 4ml, N-acetylcysteine 20% in 4 ml
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

NCT05798481
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT01265563
View directory record Official record
Conditions
Diabetic Nephropathy, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 76 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Role of HIV on Glutathione Synthesis and Oxidative Stress

NCT01355198
View directory record Official record
Conditions
HIV Infection, Erythrocyte Glutathione Deficiency
Interventions
Cysteine (as n-acetylcysteine) and glycine, Cysteine/glycine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 15, 2026, 5:24 AM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

NCT04880187
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
AXA1125, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

NCT02583672
View directory record Official record
Conditions
Gaucher Disease Type 1
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 15, 2026, 5:24 AM EDT
Withdrawn Phase 1 Interventional

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

NCT01138137
View directory record Official record
Conditions
Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Paclitaxel, N-acetylcysteine, Cisplatin
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 15, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

NAC as a Potential Treatment for Methamphetamine Dependence

NCT01063205
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence, Substance Abuse
Interventions
Placebo, N-acetylcysteine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Mucinex Exploratory Cold Study

NCT01046136
View directory record Official record
Conditions
Common Cold
Interventions
guaifenesin (Mucinex), placebo
Drug
Lead sponsor
Reckitt Benckiser Inc.
Industry
Eligibility
12 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bellevue, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

NCT03238300
View directory record Official record
Conditions
Alcohol Drinking, Control
Interventions
N-Acetylcysteine, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 19 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 15, 2026, 5:24 AM EDT
Not listed Not applicable Interventional

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

NCT01599884
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
N-acetylcysteine, Oral acetylcysteine
Drug
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
40 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

NCT02212678
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-acetylcysteine capsule
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Early Phase 1 Interventional Results available

NAC +taVNS in IDM Who Are Poor Oral Feeders

NCT04632069
View directory record Official record
Conditions
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
Interventions
N acetyl cysteine + vagus nerve stimulation
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Weeks to 5 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

NCT02445651
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 15, 2026, 5:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

NCT03104725
View directory record Official record
Conditions
Parkinson Disease, Cerebrospinal Fluid
Interventions
N-Acetylcysteine, Lumbar Puncture, Fluoroscopy
Drug · Procedure · Radiation
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

NCT03757585
View directory record Official record
Conditions
Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 15, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 15, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional

N-acetylcysteine in the Treatment of Bulimia Nervosa

NCT01033149
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
N-acetylcysteine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 15, 2026, 5:24 AM EDT